Phosphodiesterase-4 Inhibitors in Dermatology
PDE4 inhibitors are emerging as important anti-inflammatory agents in dermatology, with both oral and topical formulations now available for treating inflammatory skin conditions including psoriasis, atopic dermatitis, and seborrheic dermatitis.
Mechanism of Action
PDE4 inhibitors work by blocking the degradation of cyclic adenosine monophosphate (cAMP), an intracellular secondary messenger that regulates inflammatory responses. By preventing cAMP breakdown, these agents increase cellular cAMP concentrations, which subsequently reduces production of pro-inflammatory cytokines including TNF-α, IL-17, IL-22, and IL-23 1, 2. This upstream modulation of the inflammatory cascade makes PDE4 an attractive therapeutic target across multiple inflammatory dermatoses.
Currently Available PDE4 Inhibitors
Oral Agents
Apremilast is the first FDA-approved oral PDE4 inhibitor for dermatologic use, indicated for:
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Oral ulcers of Behçet's disease
Off-label uses include aphthous stomatitis, chronic actinic dermatitis, atopic dermatitis, cutaneous sarcoidosis, hidradenitis suppurativa, lichen planus, and discoid lupus erythematosus 1.
Oral roflumilast (originally approved for chronic obstructive pulmonary disease) has demonstrated efficacy in psoriasis and other conditions including hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Behçet's disease 1.
Topical Agents
Roflumilast cream 0.15% received FDA approval in July 2024 for mild to moderate atopic dermatitis in patients aged 6 years and older 3. The 0.3% formulation is approved for plaque psoriasis and seborrheic dermatitis 1. Roflumilast is the most potent PDE4 inhibitor available, with an in vitro IC50 of 0.7 nM—over 200 times more potent than apremilast (IC50 0.14 μM) and over 300 times more potent than crisaborole (IC50 0.24 μM) 4, 5.
Crisaborole is approved for mild to moderate atopic dermatitis and has been studied in psoriasis 2, 6.
Tapinarof cream 1% is a nonsteroidal topical aryl hydrocarbon receptor agonist (not strictly a PDE4 inhibitor but functionally similar) approved in December 2024 for atopic dermatitis in individuals aged 2 years and older 3.
Dosing Regimens
Roflumilast Cream 0.15% for Atopic Dermatitis
- Once-daily application to affected areas
- Clinical response typically seen within 4 weeks
- At 4 weeks, significantly more patients achieve validated IGA scores of 0 or 1 and EASI-75 compared to vehicle 3
Apremilast for Psoriasis
- Standard dosing follows a titration schedule to minimize gastrointestinal side effects
- Maintenance dose typically 30 mg twice daily
Topical Roflumilast for Psoriasis
- Once-daily application of 0.3% cream
- Demonstrates rapid localized response in mild to moderate psoriasis 7
Clinical Efficacy
For Atopic Dermatitis: Meta-analysis of topical PDE4 inhibitors shows significant decrease in target lesion scores (SMD -0.40; 95% CI, -0.61 to -0.18; P < .001) and higher response rates for clear or almost clear skin (RR 1.50; 95% CI, 1.33-1.70; P < .001) 8. Crisaborole and AN2898 specifically demonstrated significant improvements at both 14 and 28 days 8.
For Psoriasis: Oral roflumilast demonstrates consistent improvements in PASI and DLQI scores in moderate to severe plaque psoriasis 7. Topical formulations show rapid response in sensitive areas including face and intertriginous regions with minimal adverse effects 7.
Safety Profile and Contraindications
Topical Formulations
- Well tolerated with limited adverse effects
- Roflumilast 0.15%: Most common adverse events (≥1%) include headache, nausea, diarrhea, and vomiting
- Application site pain reported in 1.5% of roflumilast-treated patients vs 0.7% vehicle 3
- Low discontinuation rates similar to vehicle 3
- No absolute contraindications beyond hypersensitivity to components
Oral Formulations
- Gastrointestinal symptoms are the most common adverse events with oral roflumilast and apremilast 7
- Weight loss and psychiatric symptoms (depression, suicidal ideation) require monitoring with apremilast
- Avoid in pregnancy (insufficient safety data)
Key Clinical Advantages
The favorable safety profile of PDE4 inhibitors addresses a critical gap in dermatology: they provide an alternative to topical corticosteroids for chronic inflammatory conditions, avoiding risks of skin atrophy, telangiectasia, and HPA axis suppression 1. Unlike topical calcineurin inhibitors, they lack the boxed warning for theoretical malignancy risk and do not cause burning/stinging 9.
Common Pitfalls and Caveats
- Oral agents require titration to minimize GI side effects; starting at full dose increases discontinuation rates
- Topical roflumilast concentration matters: 0.15% for atopic dermatitis, 0.3% for psoriasis—using the wrong strength reduces efficacy
- Response time varies: Topical agents show improvement within 4 weeks, but maximal benefit may require 8-12 weeks of continuous use 3
- Not appropriate for severe disease requiring systemic immunosuppression: PDE4 inhibitors work best for mild to moderate disease 3, 7
- Patient expectations must be managed: While effective, PDE4 inhibitors typically show moderate rather than dramatic improvements compared to biologics
Emerging Agents
New oral PDE4 inhibitors in development include orismilast (LEO-32731), mufemilast (Hemay005), difamilast (OPA-15406), and lotamilast (E6005/RVT-501), which may offer improved efficacy or tolerability profiles 1.